Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3
At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L
Zai Lab's new medicine combination worked really well in early testing. When a medicine shows strong results early on, watch if the company moves successfully to the next testing stage.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.